NAFDAC, the National Agency for Food and Drug Administration and Control has issued an urgent safety alert nationwide.
The warning concerns the recall of specific Mivacron and Nimbex injection batches from the Nigerian market.
According to NAFDAC, the affected injections were manufactured by Aspen Pharmacare Asia Limited.
The agency disclosed this development through an official statement shared on its X platform.
This recall follows safety concerns initially raised by the Hong Kong Department of Health.
NAFDAC confirmed that one batch of Mivacron Injection 0.2 percent is affected.
In addition, five batches of Nimbex Injection 2mg per millilitre are included in the recall.
The action was taken as a precaution to protect patient safety nationwide.
Investigations revealed deficiencies in the manufacturer’s manual visual inspection process.
As a result, some glass particles in the ampoules may have gone undetected.
Consequently, the manufacturer initiated a voluntary recall to prevent potential harm.
Mivacron and Nimbex injections contain mivacurium and cisatracurium as active ingredients.
These medicines are prescription-only drugs used alongside general anaesthesia during surgeries.
Therefore, their quality and safety remain critical to patient outcomes.
NAFDAC has advised healthcare providers to remain vigilant when handling injectable medicines.
The agency also urged hospitals to immediately quarantine affected batches if identified.
Meanwhile, distributors and retailers should stop the sale of the recalled products.
Furthermore, NAFDAC encouraged Nigerians to report any suspected substandard medicines promptly.
Reports can be made at NAFDAC offices nationwide or through official e-reporting platforms.
This proactive reporting supports faster regulatory action and public health protection.
NAFDAC reaffirmed its commitment to ensuring safe, effective, and quality medicines nationwide.
The agency emphasized continuous monitoring to safeguard public health across Nigeria.
ChatGPT can make mistakes. Check
